Lin Xia

Fujian Provincial Key Laboratory Of Innovative Drug Target Research
Xiamen, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors.

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: February 06, 2025

PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity.

PILRα on tumor cells interacts with the T cell surface protein CD99 to suppress antitumor immunity.

Journal: Nature cancer

Published: January 10, 2024

Hsa_circ_0001741 Suppresses Ovarian Cancer Cell Proliferations Through Adsorption of miR-188-5p and Promotion of FOXN2 Expression.

Hsa_circ_0001741 Suppresses Ovarian Cancer Cell Proliferations Through Adsorption of miR-188-5p and Promotion of FOXN2 Expression.

Journal: Molecular biotechnology

Published: November 09, 2022

A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.

A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.

Journal: Cellular & molecular immunology

Published: June 30, 2022

Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.

Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.

Journal: Nucleic acids research

Published: December 20, 2021

Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19.

Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19.

Journal: Science bulletin

Published: September 24, 2021

BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.

BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: December 09, 2020

Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition.

Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition.

Journal: Cancer immunology research

Published: May 15, 2020

Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development.

Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development.

Journal: Antiviral research

Published: August 19, 2019

Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.

Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.

Journal: Human vaccines & immunotherapeutics

Published: October 21, 2017

A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys.

A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys.

Journal: Protein & cell

Published: July 06, 2017

Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection.

Active evolution of memory B-cells specific to viral gH/gL/pUL128/130/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection.

Journal: Oncotarget

Published: May 14, 2017

Showing 1-12 of 16

Last Updated: 09/26/2026